Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery

Yıldız-Peköz, Ayca; Akbal, Ozlem; Tekarslan, S Hande; Sağirli, A. Olcay; Mülazımoğlu, Lütfiye; Morina, Deniz; Cevher, Erdal

doi:10.1089/jamp.2017.1378

Cited by 17 publications

(9 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The GA-crosslinked MS were rinsed thoroughly with distilled water, and further treated with 4 wt% glycine solution to react with the aldehyde groups in the residual GA [ 45 ]; thus, the potential toxicity was greatly minimized. With regard to the appropriate concentrations of MS in the cytotoxicity studies, most researchers performed the cytotoxicity analysis at a concentration of 10 or 20 mg/mL of the MS [ [46] , [47] , [48] , [49] ]. A previous report by Campos et al showed that when increased the concentrations of GA-crosslinked chitosan–PVA microparticles (CCPMS) to 10.0% (v/v), there was no significant difference in the cell viability compared to the 2.0% (v/v) MS [ 50 ].…”

Section: Resultsmentioning

confidence: 99%

Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation

Chen

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation

Chen

et al. 2021

Bioactive Materials

View full text Add to dashboard Cite

“…As a lower respiratory tract infection, the overall hospitalization rate of pneumonia is high [ 21 ]. Pneumonia is usually caused by bacteria and viruses, which is a leading disorder leading to the death of children [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Upregulated expression of long non-coding RNA MEG3 serves as a prognostic biomarker in severe pneumonia children and its regulatory mechanism

Guo

Zhang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Severe pneumonia is a high-mortality disorder in children. The expression and underlying effects of lncRNA maternally expressed 3 (MEG3) were detected. The relationships between MEG3 and other parameters were reported by Pearson correlation. The prognostic importance of MEG3 was assessed by Kaplan-Meier (K-M) curve and COX analysis and its diagnostic potential was uncovered by the receiver operating characteristic (ROC) curve. Luciferase activity assay was performed to demonstrate the target gene of MEG3. Elevated expression of MEG3 and reduced microRNA-29 c (miR-29 c) were evaluated in severe pneumonia children, and a negative relationship between MEG3 and miR-29 c was propounded. MEG3 might function as an independent prognostic indicator. The diagnostic efficiency of MEG3 was also indicated for severe pneumonia children. In MRC-5 cell models and MH-S cell models, lipopolysaccharide (LPS) contributed to the increased expression of MEG3. Interference of MEG3 restricted the upregulation of MEG3 triggered by LPS. Silenced MEG3 protected MRC-5 and MH-S cells against damages managed by LPS on cell apoptosis, viability, and inflammation. MiR-29 c was a ceRNA of MEG3 and the absence of MEG3 abrogated the decreased expression of miR-29 c caused by LPS. Overall, the increased expression of MEG3 and the reduced levels of miR-29 c were identified in severe pneumonia. Prognostic and diagnostic significances of MEG3 provided a novel perspective for severe pneumonia. Disruption of MEG3 alleviated cell injury and inflammation as characterized by high LPS by binding miR-29 c.

show abstract

“…Doripenem, a drug belonging to this class, is widely used in the treatment of pneumonia and, similar to others of its class, has low oral bioavailability and is administered intravenously. Yildiz-Peköz et al [ 46 ] proposed doripenem loading in chitosan microparticles, whose properties were optimized using lactose, trehalose and leucine in different concentrations. The in vitro test results showed that microparticles allowed controlled release considered suitable for drugs administered by the pulmonary route.…”

Section: Polymeric Microparticles In Biological Testsmentioning

confidence: 99%

Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of In Vitro and In Vivo Studies

Silva

Menezes

Oliveira

et al. 2023

IJMS

View full text Add to dashboard Cite

Microparticulate systems such as microparticles, microspheres, microcapsules or any particle in a micrometer scale (usually of 1–1000 µm) are widely used as drug delivery systems, because they offer higher therapeutic and diagnostic performance compared to conventional drug delivery forms. These systems can be manufactured with many raw materials, especially polymers, most of which have been effective in improving the physicochemical properties and biological activities of active compounds. This review will focus on the in vivo and in vitro application in the last decade (2012 to 2022) of different active pharmaceutical ingredients microencapsulated in polymeric or lipid matrices, the main formulation factors (excipients and techniques) and mostly their biological activities, with the aim of introducing and discussing the potential applicability of microparticulate systems in the pharmaceutical field.

show abstract

Preparation and Characterization of Doripenem-Loaded Microparticles for Pulmonary Delivery

Cited by 17 publications

References 46 publications

Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation

Immobilized thrombin on X-ray radiopaque polyvinyl alcohol/chitosan embolic microspheres for precise localization and topical blood coagulation

Upregulated expression of long non-coding RNA MEG3 serves as a prognostic biomarker in severe pneumonia children and its regulatory mechanism

Microparticles in the Development and Improvement of Pharmaceutical Formulations: An Analysis of In Vitro and In Vivo Studies

Contact Info

Product

Resources

About